PFS
Fig. 1 · Panel Central
Panel Central 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Narikazu Boku, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Kensei Yamaguchi, Ken Kato, Shigenori Kadowaki, Kunihiro Tsuji, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Sun Young Rha, Keun-Wook Lee, Ik-Joo Chung, Sun Jin Sym, Li-Tzong Chen, Jen-Shi Chen, Li-Yuan Bai, Takashi Nakada, Shunsuke Hagihara, Reina Makino, Eiji Nishiyama, Yoon-Koo Kang
Gastric Cancer 27(6) 1287-1301
BACKGROUND: Nivolumab + chemotherapy is now a standard of care for HER2-negative, previously untreated, unresectable or recurrent gastric/gastroesophageal junction cancer (advanced gastric cancer), but long-term follow-up data of clinical trials are limited. METHODS: ATTRACTON-4 was a phase 3, double-blind, placebo-controlled trial in Japan, South Korea, and Taiwan. Patients were randomized to either nivolumab or placebo, both combined with the physician's choice of SOX (oral S-1 [tegafur-gimeracil-oteracil potassium] + oxaliplatin) or CAPOX (capecitabine + oxaliplatin). We report the primary endpoints-centrally assessed progression-free survival (PFS) and overall survival (OS)-and landmark analyses of OS among patients alive using 3-year follow-up data. RESULTS: At the cutoff date (May 10, 2021), 17/359 patients in the nivolumab + chemotherapy group and 6/358 in the placebo + chemotherapy group were continuing study treatment. PFS (centrally assessed) was longer in the nivolumab + chemotherapy group (median 10.94 vs. 8.48 months; hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.55-0.82). Although OS did not differ between the two groups (median 17.45 vs. 17.15 months; HR 0.89, 95% CI 0.75-1.05), the landmark analysis of OS, calculating HRs at each landmark time point (every month), was getting numerically better in the nivolumab + chemotherapy group over time. Approximately 80% of patients who achieved complete response in the nivolumab + chemotherapy group were alive at 3 years. No new safety signals or major late-onset select treatment-related adverse events were observed for nivolumab + chemotherapy. CONCLUSION: This 3-year follow-up of ATTRACTION-4 confirmed the long-term clinical benefit and manageable safety of nivolumab + chemotherapy in patients with previously untreated advanced gastric cancer. TRIAL REGISTRATION: NCT02746796.
3 个 Figure · 4 个 KM 面板
Fig. 1 a Centrally assessed PFS. b Investigator-assessed PFS. c Forest plot analysis of centrally assessed PFS. CAPOX capecitabine plus oxaliplatin, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, eCRF electronic case report form, HR hazard ratio, IWRS interactive web response system, n/c not countable, PD-L1 programmed death ligand 1, PFS progression-free survival, SOX S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin
Fig. 1 · Panel Central
Panel Central 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel Investigator
Panel Investigator 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 a OS. b Forest plot analysis of OS. c Landmark analysis of OS. CAPOX capecitabine plus oxaliplatin, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, eCRF electronic case report form, HR hazard ratio, IWRS interactive web response system, n/c not countable, OS overall survival, PD-L1 programmed death ligand 1, SOX S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 DOR in patients whose best objective response was CR or PR. CI confidence interval, CR complete response, DOR duration of response, PR partial response
Fig. 3 · Panel DOR_in_patients_with_CR_PR
Panel DOR_in_patients_with_CR_PR 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。